Quote | Nuvation Bio Inc. Class A (NYSE:NUVB)
Last: | $3.74 |
---|---|
Change Percent: | -1.63% |
Open: | $3.75 |
Close: | $3.74 |
High: | $3.83 |
Low: | $3.64 |
Volume: | 1,238,485 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Nuvation Bio Inc. Class A (NYSE:NUVB)
2024-07-23 16:17:17 ET More on Nuvation Bio Nuvation Bio: A Potentially Transformative Acquisition Seeking Alpha’s Quant Rating on Nuvation Bio Historical earnings data for Nuvation Bio Financial information for Nuvation Bio Read the full art...
Company to present pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies at the European Society of Medical Oncology (ESMO) Congress 2024, which will support Nuvation Bio’s New Drug Application (NDA) in the United States Company to present data from the global, pivotal ...
Message Board Posts | Nuvation Bio Inc. Class A (NYSE:NUVB)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Nuvation Bio Inc. Class A Company Name:
NUVB Stock Symbol:
NYSE Market:
Nuvation Bio Inc. Class A Website:
Company to present pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies at the European Society of Medical Oncology (ESMO) Congress 2024, which will support Nuvation Bio’s New Drug Application (NDA) in the United States Company to present data from the global, pivotal ...
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at t...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced today that David Hung, M.D., Founder, President, and Chief Executive Officer of Nu...